MX2007015950A - Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma. - Google Patents
Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma.Info
- Publication number
- MX2007015950A MX2007015950A MX2007015950A MX2007015950A MX2007015950A MX 2007015950 A MX2007015950 A MX 2007015950A MX 2007015950 A MX2007015950 A MX 2007015950A MX 2007015950 A MX2007015950 A MX 2007015950A MX 2007015950 A MX2007015950 A MX 2007015950A
- Authority
- MX
- Mexico
- Prior art keywords
- carcinoma
- immune response
- cancer
- present
- multivalent entrain
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 title abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
La presente invencion proporciona un metodo para tratar una enfermedad proliferativa celular tal como cancer al proporcionar a un sujeto con necesidad de la misma una composicion inmunogenica que comprende plasmido y peptido(s) o analogos de los mismos. En modalidades de la presente invencion se proporcionan metodos y composiciones para inducir, transportar y/o amplificar la respuesta inmune para epitopes restringidos MHC Clase I de antigenos de carcinoma para generar una respuesta inmune anti-cancer efectiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69158105P | 2005-06-17 | 2005-06-17 | |
PCT/US2006/023499 WO2006138568A2 (en) | 2005-06-17 | 2006-06-16 | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007015950A true MX2007015950A (es) | 2008-04-04 |
Family
ID=37309646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007015950A MX2007015950A (es) | 2005-06-17 | 2006-06-16 | Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma. |
Country Status (13)
Country | Link |
---|---|
US (2) | US8084592B2 (es) |
EP (2) | EP2465530A1 (es) |
JP (1) | JP2008543869A (es) |
KR (1) | KR20080033271A (es) |
CN (1) | CN101687020A (es) |
AU (1) | AU2006259221B8 (es) |
BR (1) | BRPI0611795A2 (es) |
CA (1) | CA2612518A1 (es) |
IL (1) | IL188107A (es) |
MX (1) | MX2007015950A (es) |
NZ (2) | NZ564360A (es) |
SG (1) | SG162818A1 (es) |
WO (1) | WO2006138568A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
JP2008526760A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
CA2612516C (en) | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
EP2371850A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
AU2007272785A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes |
WO2009033687A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Spantide ii and bfgf (119-126) for therapeutic applications |
CA2699255A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
CN102973950B (zh) * | 2011-09-06 | 2015-05-27 | 四川百利药业有限责任公司 | Prame、wt1双价肿瘤dna疫苗 |
EP2908851A1 (en) * | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
US10462442B2 (en) * | 2012-12-20 | 2019-10-29 | Brett I. Walker | Apparatus, systems and methods for monitoring vehicular activity |
WO2016207754A1 (en) * | 2015-06-24 | 2016-12-29 | Corephotonics Ltd. | Low profile tri-axis actuator for folded lens camera |
US20220372165A1 (en) | 2021-05-05 | 2022-11-24 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
US20230190805A1 (en) * | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2606601A (en) | 1948-12-14 | 1952-08-12 | Knoll Associates | Chair having a back rest in the form of a shell-like body |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
WO1990013659A1 (en) * | 1989-05-04 | 1990-11-15 | Genentech, Inc. | Processes and compositions for the isolation of human relaxin |
US5320886A (en) * | 1991-11-14 | 1994-06-14 | American Dental Association Health Foundation | Hydrophilic crosslinking monomers and polymers made therefrom |
ATE342356T1 (de) | 1992-11-05 | 2006-11-15 | Sloan Kettering Inst Cancer | Prostata-spezifisches membranantigen |
US5747271A (en) * | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
US5620886A (en) | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US6025191A (en) * | 1995-06-07 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
EP2286831A1 (en) | 1997-07-10 | 2011-02-23 | Mannkind Corporation | A method of inducing a CTL response |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
EP1118860A1 (en) * | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
CA2405363A1 (en) * | 2000-04-28 | 2001-11-08 | Ctl Immunotherapies Corp. | Epitope synchronization in antigen presenting cells |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
DE60219603T2 (de) | 2001-02-26 | 2007-08-30 | Kao Corp. | Behälter |
US7252824B2 (en) | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
JP3830382B2 (ja) | 2001-03-14 | 2006-10-04 | 日本碍子株式会社 | セラミック焼結体およびその製造方法 |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
CN1313617C (zh) | 2001-11-07 | 2007-05-02 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
US20040019571A1 (en) | 2002-07-26 | 2004-01-29 | Intel Corporation | Mobile communication device with electronic token repository and method |
US20070105779A1 (en) * | 2002-07-31 | 2007-05-10 | Danila Valmori | Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
CA2496888A1 (en) * | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
ATE476196T1 (de) | 2003-06-17 | 2010-08-15 | Mannkind Corp | Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke |
EP2338506A3 (en) | 2003-06-17 | 2011-10-12 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
WO2005010190A1 (en) * | 2003-07-22 | 2005-02-03 | Ludwig Institute For Cancer Research | Ssx-2 peptides presented by hla class ii molucules |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
MXPA06014769A (es) | 2004-06-17 | 2007-03-26 | Mannkind Corp | Eficiencia mejorada de la inmunoterapia al integrar metodos de diagnostico con terapeuticos. |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US20060057673A1 (en) | 2004-06-17 | 2006-03-16 | Liping Liu | Epitope analogs |
EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
EP1835932A2 (en) * | 2004-12-29 | 2007-09-26 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
JP2008526760A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
CA2612516C (en) * | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
EP2371850A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
AU2007272785A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes |
US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
US9814289B2 (en) | 2015-04-08 | 2017-11-14 | Otter Products, Llc | Protective folio case for an electronic device |
EP3636238B1 (en) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Gates with transition ramps for overhead lifting rails |
-
2006
- 2006-06-16 EP EP11166263A patent/EP2465530A1/en not_active Withdrawn
- 2006-06-16 SG SG201004452-7A patent/SG162818A1/en unknown
- 2006-06-16 MX MX2007015950A patent/MX2007015950A/es active IP Right Grant
- 2006-06-16 CN CN200680021752A patent/CN101687020A/zh active Pending
- 2006-06-16 JP JP2008517147A patent/JP2008543869A/ja active Pending
- 2006-06-16 NZ NZ564360A patent/NZ564360A/en not_active IP Right Cessation
- 2006-06-16 BR BRPI0611795-3A patent/BRPI0611795A2/pt not_active IP Right Cessation
- 2006-06-16 CA CA002612518A patent/CA2612518A1/en not_active Abandoned
- 2006-06-16 KR KR1020087001198A patent/KR20080033271A/ko not_active Application Discontinuation
- 2006-06-16 US US11/455,279 patent/US8084592B2/en not_active Expired - Fee Related
- 2006-06-16 EP EP06773350.1A patent/EP1901774B1/en not_active Not-in-force
- 2006-06-16 AU AU2006259221A patent/AU2006259221B8/en not_active Ceased
- 2006-06-16 WO PCT/US2006/023499 patent/WO2006138568A2/en active Application Filing
- 2006-06-16 NZ NZ587601A patent/NZ587601A/en not_active IP Right Cessation
-
2007
- 2007-12-13 IL IL188107A patent/IL188107A/en not_active IP Right Cessation
-
2011
- 2011-12-23 US US13/336,523 patent/US20120148613A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120148613A1 (en) | 2012-06-14 |
AU2006259221B2 (en) | 2012-10-04 |
US8084592B2 (en) | 2011-12-27 |
JP2008543869A (ja) | 2008-12-04 |
NZ564360A (en) | 2011-03-31 |
EP1901774A2 (en) | 2008-03-26 |
IL188107A (en) | 2015-03-31 |
AU2006259221A1 (en) | 2006-12-28 |
CA2612518A1 (en) | 2006-12-28 |
KR20080033271A (ko) | 2008-04-16 |
IL188107A0 (en) | 2008-03-20 |
BRPI0611795A2 (pt) | 2010-09-28 |
EP1901774B1 (en) | 2014-04-09 |
US20070003563A1 (en) | 2007-01-04 |
AU2006259221B8 (en) | 2013-02-07 |
WO2006138568A2 (en) | 2006-12-28 |
NZ587601A (en) | 2012-05-25 |
SG162818A1 (en) | 2010-07-29 |
EP2465530A1 (en) | 2012-06-20 |
WO2006138568A3 (en) | 2007-05-03 |
CN101687020A (zh) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG162818A1 (en) | Multivalent entrain-and-amplify immunotherapeutics for carcinoma | |
SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
EP3584251A3 (en) | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines | |
WO2006071983A3 (en) | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines | |
EE200100203A (et) | Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon | |
MY162850A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers | |
NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
MX2010001090A (es) | Nuevos epitopos inmunogenicos para inmunoterapia. | |
WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
WO2008008541A3 (en) | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
WO2006032472A3 (en) | Immunogenic composition for use in vaccination against staphylococcei | |
GB2434367A (en) | Improved vaccines | |
WO2008039874A3 (en) | Cancer stem cell antigen vaccines and methods | |
WO2006126981A3 (en) | Compositions and methods for mucosal vaccination | |
RU2015131033A (ru) | Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант | |
BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
WO2009002418A3 (en) | T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof | |
MX2010006984A (es) | Vacunas contra la malaria. | |
MA29244B1 (fr) | Compositions permettant d'immuniser contre une mycobacterie | |
TW200637573A (en) | Peptide for delivery of mucosal vaccines | |
UA101385C2 (ru) | Иммунологическая композиция, которая в качестве адъюванты содержит сульфолипо-циклодекстрин (sl-cd) и сапонин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |